dupilumab vs SHR-1819

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline

dupilumab · Dupixent

Marketed by Regeneron Pharmaceuticals and partners

Approved in Atopic Dermatitismonoclonal antibody
Weak signal

NCT01949311 · Phase 3 · completed

This was an explicitly described open-label extension enrolling participants from prior dupilumab atopic dermatitis trials, including the SOLO 1 and SOLO 2 programs, with 2,677 participants receiving dupilumab in a single group. The primary outcomes were safety events rather than a comparative efficacy endpoint, and there was no randomization, blinding, or control arm; therefore, the findings provide limited evidence despite the large enrollment. Its registered primary outcome on ClinicalTrials.gov is "Number of Treatment Emergent Adverse Events (TEAEs)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: November 2026 · NCT06389136 (registry estimate)

Reported efficacy

Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 (At week 16): Dupilumab Q2W 40.3% vs Matching Placebo 16.7% (met)

Result source: NCT04417894

SHR-1819

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Atopic Dermatitismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2027 · NCT07321951 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdupilumabSHR-1819
EASI-7562.6% vs 29.6%+33 vs placebo300 mg Q2W · wk 16 · n 107NCT02755649
21 other results
  • 38.1% vs 8.2% 300 mg Q4W · wk 16 · n 84 · Phase 3 · primary NCT03054428
  • 59.1% vs 29.6% 300 mg QW · wk 16 · n 110 · Phase 3 · primary NCT02755649
  • 41.5% vs 8.2% 200 mg or 300 mg Q2W · wk 16 · n 82 · Phase 3 · primary NCT03054428
  • 53% vs 10.7% 200 mg or 300 mg Q4W · wk 16 · n 83 · Phase 2/3 · primary NCT03346434
  • 62.6% vs 72.4% 300 mg EOW · wk 16 · n 331 · Phase 3 · primary NCT03738397
  • 65.2% vs 21.6% 300 mg q2w · wk 52 · n 89 · Phase 3 · secondary NCT02260986
  • 51.3% vs 14.7% 300 mg q2w · wk 16 · n 224 · Phase 3 · secondary NCT02277743
  • 44.2% vs 11.9% 300 mg q2w · wk 16 · n 233 · Phase 3 · secondary NCT02277769
  • 64.1% vs 21.6% 300 mg qw · wk 52 · n 270 · Phase 3 · secondary NCT02260986
  • 63.9% vs 23.2% 300 mg qw · wk 16 · n 319 · Phase 3 · secondary NCT02260986
  • 68.9% vs 23.2% 300 mg q2w · wk 16 · n 106 · Phase 3 · secondary NCT02260986
  • 57.3% vs 14.5% 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03912259
  • 52.5% vs 14.7% 300 mg qw · wk 16 · n 223 · Phase 3 · secondary NCT02277743
  • 48.1% vs 11.9% 300 mg qw · wk 16 · n 239 · Phase 3 · secondary NCT02277769
  • 58% vs 26.4% 300 mg Q2W · wk 16 · n 69 · Phase 3 · secondary NCT02755649
  • 69.7% vs 26.8% 300 mg Q4W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • 56.5% vs 26.4% 300 mg QW · wk 16 · n 69 · Phase 3 · secondary NCT02755649
  • 67.2% vs 26.8% 100 mg or 200 mg Q2W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • 18.2% vs 44.3% 300 mg EOW · wk 2 · n 331 · Phase 3 · secondary NCT03738397
  • 53.6% vs 19.6% 300 mg qw · wk 16 · n 97 · Phase 2 · secondary NCT02210780
  • 60.6% vs 29.2% wk 12 · n 109 · Phase 4 · secondary NCT04033367
—Trial running · NCT07309055
IGA 0/1 with 2-point improvement—Trial running · NCT06884891—Trial running · NCT07309055
EASI-9035.7% vs 7.6%+28.1 vs placebo300 mg q2w · wk 16 · n 224NCT02277743
10 other results
  • 30% vs 7.2% 300 mg q2w · wk 16 · n 233 · Phase 3 · secondary NCT02277769
  • 40.2% vs 6% 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03912259
  • 33.2% vs 7.6% 300 mg qw · wk 16 · n 223 · Phase 3 · secondary NCT02277743
  • 30.5% vs 7.2% 300 mg qw · wk 16 · n 239 · Phase 3 · secondary NCT02277769
  • 19% vs 2.4% 300 mg Q4W · wk 16 · n 84 · Phase 3 · secondary NCT03054428
  • 41.8% vs 7.3% 300 mg Q4W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • 23.2% vs 2.4% 200 mg or 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03054428
  • 25.3% vs 2.8% 200 mg or 300 mg Q4W · wk 16 · n 83 · Phase 2/3 · secondary NCT03346434
  • 30.3% vs 7.3% 100 mg or 200 mg Q2W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • 40.3% vs 61.6% 300 mg EOW · wk 16 · n 331 · Phase 3 · secondary NCT03738397
—Trial running · NCT07309055
EASI, % change0.1% vs 21.7%−21.6 vs placebo300 mg Q2W/QW · wk 36 · n 169NCT02395133
31 other results
  • 6.8% vs 21.7% 300 mg Q8W · wk 36 · n 84 · Phase 3 · primary NCT02395133
  • 3.8% vs 21.7% 300 mg Q4W · wk 36 · n 86 · Phase 3 · primary NCT02395133
  • -84.9% vs -60.9% 300 mg q2w · wk 52 · n 89 · Phase 3 · secondary NCT02260986
  • -73.9% vs -39.5% 300 mg q2w · wk 16 · n 173 · Phase 3 · secondary NCT02277743
  • -69.6% vs -33.7% 300 mg q2w · wk 16 · n 197 · Phase 3 · secondary NCT02277769
  • -80.5% vs -48.4% 300 mg q2w · wk 16 · n 92 · Phase 3 · secondary NCT02260986
  • -87.8% vs -60.9% 300 mg qw · wk 52 · n 270 · Phase 3 · secondary NCT02260986
  • -75.2% vs -39.4% 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03912259
  • -75.2% vs -39.4% 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03912259
  • -79.8% vs -46.6% 300 mg Q2W · wk 16 · n 103 · Phase 3 · secondary NCT02755649
  • -70.4% vs -35.3% 300 mg Q2W · wk 12 · n 82 · Phase 3 · secondary NCT03912259
  • -65.8% vs -29.4% 300 mg Q2W · wk 8 · n 82 · Phase 3 · secondary NCT03912259
  • -55.8% vs -19.3% 300 mg Q2W · wk 4 · n 82 · Phase 3 · secondary NCT03912259
  • -73.8% vs -39.5% 300 mg qw · wk 16 · n 162 · Phase 3 · secondary NCT02277743
  • -71.6% vs -33.7% 300 mg qw · wk 16 · n 181 · Phase 3 · secondary NCT02277769
  • -81.5% vs -48.4% 300 mg qw · wk 16 · n 269 · Phase 3 · secondary NCT02260986
  • -35.7% vs -10.6% 300 mg Q2W · wk 2 · n 82 · Phase 3 · secondary NCT03912259
  • -64.8% vs -23.6% 300 mg Q4W · wk 16 · n 84 · Phase 3 · secondary NCT03054428
  • -82.1% vs -48.6% 300 mg Q4W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • -78.2% vs -46.6% 300 mg QW · wk 16 · n 105 · Phase 3 · secondary NCT02755649
  • -65.9% vs -23.6% 200 mg or 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03054428
  • -70% vs -19.6% 200 mg or 300 mg Q4W · wk 16 · n 83 · Phase 2/3 · secondary NCT03346434
  • -78.4% vs -48.6% 100 mg or 200 mg Q2W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • -70.5% vs -20.2% 300 mg q2w · wk 16 · n 63 · Phase 2 · primary NCT01859988
  • -74% vs -23.3% 300 mg · wk 12 · n 55 · Phase 2 · primary NCT01548404
  • -75.5% vs -20.2% 300 mg qw · wk 16 · n 61 · Phase 2 · primary NCT01859988
  • -64.9% vs -20.2% 300 mg q4w · wk 16 · n 65 · Phase 2 · primary NCT01859988
  • -75.2% vs -5.8% 200 mg qw · wk 16 · n 27 · Phase 2 · primary NCT01979016
  • -67.4% vs -20.2% 200 mg q2w · wk 16 · n 60 · Phase 2 · primary NCT01859988
  • -46.7% vs -20.2% 100 mg q4w · wk 16 · n 64 · Phase 2 · primary NCT01859988
  • -75.6% vs -52.5% 300 mg · wk 4 · n 21 · Phase 2 · secondary NCT01639040
—Trial running · NCT07309055

EASI-75

dupilumab
62.6% vs 29.6%+33 vs placebo300 mg Q2W · wk 16 · n 107NCT02755649
21 other results
  • 38.1% vs 8.2% 300 mg Q4W · wk 16 · n 84 · Phase 3 · primary NCT03054428
  • 59.1% vs 29.6% 300 mg QW · wk 16 · n 110 · Phase 3 · primary NCT02755649
  • 41.5% vs 8.2% 200 mg or 300 mg Q2W · wk 16 · n 82 · Phase 3 · primary NCT03054428
  • 53% vs 10.7% 200 mg or 300 mg Q4W · wk 16 · n 83 · Phase 2/3 · primary NCT03346434
  • 62.6% vs 72.4% 300 mg EOW · wk 16 · n 331 · Phase 3 · primary NCT03738397
  • 65.2% vs 21.6% 300 mg q2w · wk 52 · n 89 · Phase 3 · secondary NCT02260986
  • 51.3% vs 14.7% 300 mg q2w · wk 16 · n 224 · Phase 3 · secondary NCT02277743
  • 44.2% vs 11.9% 300 mg q2w · wk 16 · n 233 · Phase 3 · secondary NCT02277769
  • 64.1% vs 21.6% 300 mg qw · wk 52 · n 270 · Phase 3 · secondary NCT02260986
  • 63.9% vs 23.2% 300 mg qw · wk 16 · n 319 · Phase 3 · secondary NCT02260986
  • 68.9% vs 23.2% 300 mg q2w · wk 16 · n 106 · Phase 3 · secondary NCT02260986
  • 57.3% vs 14.5% 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03912259
  • 52.5% vs 14.7% 300 mg qw · wk 16 · n 223 · Phase 3 · secondary NCT02277743
  • 48.1% vs 11.9% 300 mg qw · wk 16 · n 239 · Phase 3 · secondary NCT02277769
  • 58% vs 26.4% 300 mg Q2W · wk 16 · n 69 · Phase 3 · secondary NCT02755649
  • 69.7% vs 26.8% 300 mg Q4W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • 56.5% vs 26.4% 300 mg QW · wk 16 · n 69 · Phase 3 · secondary NCT02755649
  • 67.2% vs 26.8% 100 mg or 200 mg Q2W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • 18.2% vs 44.3% 300 mg EOW · wk 2 · n 331 · Phase 3 · secondary NCT03738397
  • 53.6% vs 19.6% 300 mg qw · wk 16 · n 97 · Phase 2 · secondary NCT02210780
  • 60.6% vs 29.2% wk 12 · n 109 · Phase 4 · secondary NCT04033367
SHR-1819
—Trial running · NCT07309055

IGA 0/1 with 2-point improvement

dupilumab
—Trial running · NCT06884891
SHR-1819
—Trial running · NCT07309055

EASI-90

dupilumab
35.7% vs 7.6%+28.1 vs placebo300 mg q2w · wk 16 · n 224NCT02277743
10 other results
  • 30% vs 7.2% 300 mg q2w · wk 16 · n 233 · Phase 3 · secondary NCT02277769
  • 40.2% vs 6% 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03912259
  • 33.2% vs 7.6% 300 mg qw · wk 16 · n 223 · Phase 3 · secondary NCT02277743
  • 30.5% vs 7.2% 300 mg qw · wk 16 · n 239 · Phase 3 · secondary NCT02277769
  • 19% vs 2.4% 300 mg Q4W · wk 16 · n 84 · Phase 3 · secondary NCT03054428
  • 41.8% vs 7.3% 300 mg Q4W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • 23.2% vs 2.4% 200 mg or 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03054428
  • 25.3% vs 2.8% 200 mg or 300 mg Q4W · wk 16 · n 83 · Phase 2/3 · secondary NCT03346434
  • 30.3% vs 7.3% 100 mg or 200 mg Q2W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • 40.3% vs 61.6% 300 mg EOW · wk 16 · n 331 · Phase 3 · secondary NCT03738397
SHR-1819
—Trial running · NCT07309055

EASI, % change

dupilumab
0.1% vs 21.7%−21.6 vs placebo300 mg Q2W/QW · wk 36 · n 169NCT02395133
31 other results
  • 6.8% vs 21.7% 300 mg Q8W · wk 36 · n 84 · Phase 3 · primary NCT02395133
  • 3.8% vs 21.7% 300 mg Q4W · wk 36 · n 86 · Phase 3 · primary NCT02395133
  • -84.9% vs -60.9% 300 mg q2w · wk 52 · n 89 · Phase 3 · secondary NCT02260986
  • -73.9% vs -39.5% 300 mg q2w · wk 16 · n 173 · Phase 3 · secondary NCT02277743
  • -69.6% vs -33.7% 300 mg q2w · wk 16 · n 197 · Phase 3 · secondary NCT02277769
  • -80.5% vs -48.4% 300 mg q2w · wk 16 · n 92 · Phase 3 · secondary NCT02260986
  • -87.8% vs -60.9% 300 mg qw · wk 52 · n 270 · Phase 3 · secondary NCT02260986
  • -75.2% vs -39.4% 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03912259
  • -75.2% vs -39.4% 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03912259
  • -79.8% vs -46.6% 300 mg Q2W · wk 16 · n 103 · Phase 3 · secondary NCT02755649
  • -70.4% vs -35.3% 300 mg Q2W · wk 12 · n 82 · Phase 3 · secondary NCT03912259
  • -65.8% vs -29.4% 300 mg Q2W · wk 8 · n 82 · Phase 3 · secondary NCT03912259
  • -55.8% vs -19.3% 300 mg Q2W · wk 4 · n 82 · Phase 3 · secondary NCT03912259
  • -73.8% vs -39.5% 300 mg qw · wk 16 · n 162 · Phase 3 · secondary NCT02277743
  • -71.6% vs -33.7% 300 mg qw · wk 16 · n 181 · Phase 3 · secondary NCT02277769
  • -81.5% vs -48.4% 300 mg qw · wk 16 · n 269 · Phase 3 · secondary NCT02260986
  • -35.7% vs -10.6% 300 mg Q2W · wk 2 · n 82 · Phase 3 · secondary NCT03912259
  • -64.8% vs -23.6% 300 mg Q4W · wk 16 · n 84 · Phase 3 · secondary NCT03054428
  • -82.1% vs -48.6% 300 mg Q4W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • -78.2% vs -46.6% 300 mg QW · wk 16 · n 105 · Phase 3 · secondary NCT02755649
  • -65.9% vs -23.6% 200 mg or 300 mg Q2W · wk 16 · n 82 · Phase 3 · secondary NCT03054428
  • -70% vs -19.6% 200 mg or 300 mg Q4W · wk 16 · n 83 · Phase 2/3 · secondary NCT03346434
  • -78.4% vs -48.6% 100 mg or 200 mg Q2W · wk 16 · n 122 · Phase 3 · secondary NCT03345914
  • -70.5% vs -20.2% 300 mg q2w · wk 16 · n 63 · Phase 2 · primary NCT01859988
  • -74% vs -23.3% 300 mg · wk 12 · n 55 · Phase 2 · primary NCT01548404
  • -75.5% vs -20.2% 300 mg qw · wk 16 · n 61 · Phase 2 · primary NCT01859988
  • -64.9% vs -20.2% 300 mg q4w · wk 16 · n 65 · Phase 2 · primary NCT01859988
  • -75.2% vs -5.8% 200 mg qw · wk 16 · n 27 · Phase 2 · primary NCT01979016
  • -67.4% vs -20.2% 200 mg q2w · wk 16 · n 60 · Phase 2 · primary NCT01859988
  • -46.7% vs -20.2% 100 mg q4w · wk 16 · n 64 · Phase 2 · primary NCT01859988
  • -75.6% vs -52.5% 300 mg · wk 4 · n 21 · Phase 2 · secondary NCT01639040
SHR-1819
—Trial running · NCT07309055
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SHR-1819: no structured comparison results are available for Atopic Dermatitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. dupilumab: 4 of 4 rows · SHR-1819: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricdupilumab
Dropout rate
51.6%a
NCT01949311 · Phase 3 · monotherapy
show 51 more results
7.1%300 mg q2w
NCT02277743 · Phase 3
11.7%300 mg qw
NCT02277743 · Phase 3
5.6%300 mg q2w
NCT02277769 · Phase 3
7.5%300 mg qw
NCT02277769 · Phase 3
12.3%300 mg q2w
NCT02260986 · Phase 3
12.9%300 mg qw
NCT02260986 · Phase 3
8.3%300 mg Q2W/QW
NCT02395133 · Phase 3
11.6%300 mg Q4W
NCT02395133 · Phase 3
10.7%300 mg Q8W
NCT02395133 · Phase 3
95.2%300 mg Q4W
NCT03054428 · Phase 3
—200 mg or 300 mg
NCT03054428 · Phase 3
96.3%200 mg or 300 mg Q2W
NCT03054428 · Phase 3
n/a: no completion milestone300 mg Q4W
NCT03345914 · Phase 3 · combination
n/a: no completion milestone100 mg or 200 mg Q2W
NCT03345914 · Phase 3 · combination
98.8%200 mg or 300 mg Q4W
NCT03346434 · Phase 2/3 · combination
0%6 mg/kg
NCT03346434 · Phase 2/3
0%6 mg/kg
NCT03346434 · Phase 2/3
0%3 mg/kg
NCT03346434 · Phase 2/3
10%3 mg/kg
NCT03346434 · Phase 2/3
10.4%Q2W
NCT04417894 · Phase 3
3.2%
NCT05590585 · Phase 4 · registry result, not featured evidence
17.6%
NCT03293030 · Phase 4 · registry result, not featured evidence
29.4%
NCT03667014 · Phase 4 · registry result, not featured evidence
—Atopic Dermatitis Participant
NCT04718870 · Phase 4 · registry result, not featured evidence
0%Atopic Dermatitis Participants
NCT04718870 · Phase 4 · registry result, not featured evidence
20%
NCT04823130 · Phase 4 · registry result, not featured evidence
—DB Period: Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
3.9%Dupilumab/Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
—OLE Period: Dupilumab/Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
0%
NCT04447417 · Phase 4 · registry result, not featured evidence
6.9%300 mg EOW
NCT03738397 · Phase 3 · registry result, not featured evidence
7.3%300 mg Q2W
NCT03912259 · Phase 3 · registry result, not featured evidence
92.5%300 mg Q2W
NCT02755649 · Phase 3 · registry result, not featured evidence · combination
92.7%300 mg QW
NCT02755649 · Phase 3 · registry result, not featured evidence · combination
0%
NCT03359356 · Phase 2 · registry result, not featured evidence
—4 mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
—4 mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
0%4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
0%4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
0%2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
0%2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
8.2%300 mg qw
NCT02210780 · Phase 2 · registry result, not featured evidence
3.7%200 mg qw
NCT01979016 · Phase 2 · registry result, not featured evidence
18.8%300 mg q2w
NCT01859988 · Phase 2 · registry result, not featured evidence
15.4%300 mg q4w
NCT01859988 · Phase 2 · registry result, not featured evidence
17.5%300 mg qw
NCT01859988 · Phase 2 · registry result, not featured evidence
45.2%200 mg q2w
NCT01859988 · Phase 2 · registry result, not featured evidence
35.4%100 mg q4w
NCT01859988 · Phase 2 · registry result, not featured evidence
25.5%300 mg
NCT01548404 · Phase 2 · registry result, not featured evidence
—300 mg
NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy
0%300 mg QW
NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy
Discontinued due to AEs
4%a
NCT01949311 · Phase 3 · monotherapy
show 51 more results
2.7%300 mg q2w
NCT02277743 · Phase 3
2.7%300 mg qw
NCT02277743 · Phase 3
0.9%300 mg q2w
NCT02277769 · Phase 3
1.7%300 mg qw
NCT02277769 · Phase 3
0%300 mg q2w
NCT02260986 · Phase 3
3.4%300 mg qw
NCT02260986 · Phase 3
0%300 mg Q2W/QW
NCT02395133 · Phase 3
3.5%300 mg Q4W
NCT02395133 · Phase 3
1.2%300 mg Q8W
NCT02395133 · Phase 3
—300 mg Q4W
NCT03054428 · Phase 3
—200 mg or 300 mg
NCT03054428 · Phase 3
—200 mg or 300 mg Q2W
NCT03054428 · Phase 3
—300 mg Q4W
NCT03345914 · Phase 3 · combination
—100 mg or 200 mg Q2W
NCT03345914 · Phase 3 · combination
—200 mg or 300 mg Q4W
NCT03346434 · Phase 2/3 · combination
—6 mg/kg
NCT03346434 · Phase 2/3
—6 mg/kg
NCT03346434 · Phase 2/3
—3 mg/kg
NCT03346434 · Phase 2/3
—3 mg/kg
NCT03346434 · Phase 2/3
—Q2W
NCT04417894 · Phase 3
—
NCT05590585 · Phase 4 · registry result, not featured evidence
—
NCT03293030 · Phase 4 · registry result, not featured evidence
—
NCT03667014 · Phase 4 · registry result, not featured evidence
—Atopic Dermatitis Participant
NCT04718870 · Phase 4 · registry result, not featured evidence
—Atopic Dermatitis Participants
NCT04718870 · Phase 4 · registry result, not featured evidence
—
NCT04823130 · Phase 4 · registry result, not featured evidence
—DB Period: Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
0.8%Dupilumab/Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
—OLE Period: Dupilumab/Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
—
NCT04447417 · Phase 4 · registry result, not featured evidence
0.9%300 mg EOW
NCT03738397 · Phase 3 · registry result, not featured evidence
4.9%300 mg Q2W
NCT03912259 · Phase 3 · registry result, not featured evidence
—300 mg Q2W
NCT02755649 · Phase 3 · registry result, not featured evidence · combination
—300 mg QW
NCT02755649 · Phase 3 · registry result, not featured evidence · combination
—
NCT03359356 · Phase 2 · registry result, not featured evidence
—4 mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
—4 mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
—4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
—4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
—2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
—2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
5.2%300 mg qw
NCT02210780 · Phase 2 · registry result, not featured evidence
3.7%200 mg qw
NCT01979016 · Phase 2 · registry result, not featured evidence
1.6%300 mg q2w
NCT01859988 · Phase 2 · registry result, not featured evidence
1.5%300 mg q4w
NCT01859988 · Phase 2 · registry result, not featured evidence
3.2%300 mg qw
NCT01859988 · Phase 2 · registry result, not featured evidence
4.8%200 mg q2w
NCT01859988 · Phase 2 · registry result, not featured evidence
3.1%100 mg q4w
NCT01859988 · Phase 2 · registry result, not featured evidence
1.8%300 mg
NCT01548404 · Phase 2 · registry result, not featured evidence
—300 mg
NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy
0%300 mg QW
NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy
Serious AEs
10.6%a
NCT01949311 · Phase 3 · monotherapy
show 51 more results
3.1%300 mg q2w
NCT02277743 · Phase 3
0.9%300 mg qw
NCT02277743 · Phase 3
2.5%300 mg q2w
NCT02277769 · Phase 3
3.8%300 mg qw
NCT02277769 · Phase 3
3.6%300 mg q2w
NCT02260986 · Phase 3
3.8%300 mg qw
NCT02260986 · Phase 3
3.6%300 mg Q2W/QW
NCT02395133 · Phase 3
4.6%300 mg Q4W
NCT02395133 · Phase 3
3.6%300 mg Q8W
NCT02395133 · Phase 3
0%300 mg Q4W
NCT03054428 · Phase 3
0%200 mg or 300 mg
NCT03054428 · Phase 3
—200 mg or 300 mg Q2W
NCT03054428 · Phase 3
2.5%300 mg Q4W
NCT03345914 · Phase 3 · combination
0%100 mg or 200 mg Q2W
NCT03345914 · Phase 3 · combination
0%200 mg or 300 mg Q4W
NCT03346434 · Phase 2/3 · combination
0%6 mg/kg
NCT03346434 · Phase 2/3
0%6 mg/kg
NCT03346434 · Phase 2/3
10%3 mg/kg
NCT03346434 · Phase 2/3
10%3 mg/kg
NCT03346434 · Phase 2/3
4.5%Q2W
NCT04417894 · Phase 3
5.6%
NCT05590585 · Phase 4 · registry result, not featured evidence
0%
NCT03293030 · Phase 4 · registry result, not featured evidence
0%
NCT03667014 · Phase 4 · registry result, not featured evidence
0%Atopic Dermatitis Participant
NCT04718870 · Phase 4 · registry result, not featured evidence
—Atopic Dermatitis Participants
NCT04718870 · Phase 4 · registry result, not featured evidence
3.2%
NCT04823130 · Phase 4 · registry result, not featured evidence
1.6%DB Period: Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
—Dupilumab/Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
0.8%OLE Period: Dupilumab/Dupilumab
NCT04033367 · Phase 4 · registry result, not featured evidence
0%
NCT04447417 · Phase 4 · registry result, not featured evidence
2.1%300 mg EOW
NCT03738397 · Phase 3 · registry result, not featured evidence
1.2%300 mg Q2W
NCT03912259 · Phase 3 · registry result, not featured evidence
1.9%300 mg Q2W
NCT02755649 · Phase 3 · registry result, not featured evidence · combination
2.7%300 mg QW
NCT02755649 · Phase 3 · registry result, not featured evidence · combination
2.5%
NCT03359356 · Phase 2 · registry result, not featured evidence
5%4 mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
10.5%4 mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
—4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
—4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
5%2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
0%2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
3.1%300 mg qw
NCT02210780 · Phase 2 · registry result, not featured evidence
0%200 mg qw
NCT01979016 · Phase 2 · registry result, not featured evidence
3.1%300 mg q2w
NCT01859988 · Phase 2 · registry result, not featured evidence
4.6%300 mg q4w
NCT01859988 · Phase 2 · registry result, not featured evidence
1.6%300 mg qw
NCT01859988 · Phase 2 · registry result, not featured evidence
1.6%200 mg q2w
NCT01859988 · Phase 2 · registry result, not featured evidence
7.7%100 mg q4w
NCT01859988 · Phase 2 · registry result, not featured evidence
1.8%300 mg
NCT01548404 · Phase 2 · registry result, not featured evidence
0%300 mg
NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy
—300 mg QW
NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy
Most frequent reported AEs
a
nasopharyngitis 28.9%
dermatitis atopic 16.7%
upper respiratory tract infection 13.6%
NCT01949311 · Phase 3 · monotherapy
show 44 more results
300 mg q2w
dermatitis atopic 15.3% (placebo 29.7%)
nasopharyngitis 11.8% (placebo 9.9%)
headache 9.2% (placebo 5.9%)
NCT02277743 · Phase 3
300 mg qw
injection site reaction 18.8% (placebo 5.9%)
nasopharyngitis 11.9% (placebo 9.9%)
dermatitis atopic 9.6% (placebo 29.7%)
NCT02277743 · Phase 3
300 mg q2w
dermatitis atopic 14.4% (placebo 35%)
injection site reaction 13.6% (placebo 6.4%)
nasopharyngitis 9.7% (placebo 10.7%)
NCT02277769 · Phase 3
300 mg qw
dermatitis atopic 16.5% (placebo 35%)
injection site reaction 13.1% (placebo 6.4%)
headache 9.7% (placebo 5.1%)
NCT02277769 · Phase 3
300 mg q2w
dermatitis atopic 36.4% (placebo 51.1%)
nasopharyngitis 23.6% (placebo 19.7%)
injection site reaction 14.5% (placebo 7.6%)
NCT02260986 · Phase 3
300 mg qw
dermatitis atopic 28.9% (placebo 51.1%)
nasopharyngitis 20% (placebo 19.7%)
injection site reaction 19% (placebo 7.6%)
NCT02260986 · Phase 3
300 mg Q2W/QW
dermatitis atopic 20.4% (placebo 48.8%)
nasopharyngitis 19.2% (placebo 13.4%)
upper respiratory tract infection 7.8% (placebo 7.3%)
NCT02395133 · Phase 3
300 mg Q4W
dermatitis atopic 34.5% (placebo 48.8%)
nasopharyngitis 12.6% (placebo 13.4%)
bronchitis 5.7% (placebo 1.2%)
NCT02395133 · Phase 3
300 mg Q8W
dermatitis atopic 32.1% (placebo 48.8%)
nasopharyngitis 13.1% (placebo 13.4%)
upper respiratory tract infection 8.3% (placebo 7.3%)
NCT02395133 · Phase 3
300 mg Q4W
dermatitis atopic 19.3% (placebo 24.7%)
nasopharyngitis 12% (placebo 4.7%)
upper respiratory tract infection 8.4% (placebo 17.6%)
NCT03054428 · Phase 3
200 mg or 300 mg
dermatitis atopic 18.3% (placebo 24.7%)
upper respiratory tract infection 12.2% (placebo 17.6%)
headache 11% (placebo 10.6%)
NCT03054428 · Phase 3
300 mg Q4W
nasopharyngitis 12.5% (placebo 6.7%)
upper respiratory tract infection 11.7% (placebo 10%)
dermatitis atopic 6.7% (placebo 14.2%)
NCT03345914 · Phase 3 · combination
100 mg or 200 mg Q2W
upper respiratory tract infection 9.8% (placebo 10%)
dermatitis atopic 8.2% (placebo 14.2%)
nasopharyngitis 6.6% (placebo 6.7%)
NCT03345914 · Phase 3 · combination
200 mg or 300 mg Q4W
dermatitis atopic 14.5% (placebo 30.8%)
nasopharyngitis 8.4% (placebo 9%)
upper respiratory tract infection 6% (placebo 9%)
NCT03346434 · Phase 2/3 · combination
6 mg/kg
nasopharyngitis 20% (placebo 9%)
cough 10% (placebo 6.4%)
dermatitis atopic 10% (placebo 30.8%)
NCT03346434 · Phase 2/3
6 mg/kg
cough 10% (placebo 6.4%)
nasopharyngitis 10% (placebo 9%)
skin abrasion 10% (placebo 0%)
NCT03346434 · Phase 2/3
3 mg/kg
pyrexia 20% (placebo 9%)
constipation 10% (placebo 0%)
cough 10% (placebo 6.4%)
NCT03346434 · Phase 2/3
3 mg/kg
dermatitis atopic 10% (placebo 30.8%)
impetigo 10% (placebo 7.7%)
nasopharyngitis 10% (placebo 9%)
NCT03346434 · Phase 2/3
Q2W
nasopharyngitis 23.9% (placebo 12.1%)
covid-19 16.4% (placebo 21.2%)
upper respiratory tract infection 10.4% (placebo 4.5%)
NCT04417894 · Phase 3
eye irritation 35.3%
oral/facial herpes simplex 17.6%
covid19 (moderate) 5.9%
NCT03293030 · Phase 4 · registry result, not featured evidence
eye redness 2.9%
eyelid swelling 2.9%
facial erythema 2.9%
NCT03667014 · Phase 4 · registry result, not featured evidence
dermatitis atopic 39.1%
medical device site haemorrhage 26.1%
upper respiratory tract infection 17.4%
NCT04718870 · Phase 4 · registry result, not featured evidence
headache 22.6%
dermatitis atopic 9.7%
conjunctivitis 6.5%
NCT04823130 · Phase 4 · registry result, not featured evidence
conjunctivitis 9.4% (placebo 4.9%)
headache 7.1% (placebo 8.2%)
dermatitis atopic 3.1% (placebo 13.1%)
NCT04033367 · Phase 4 · registry result, not featured evidence
accidental overdose 12.3% (placebo 0%)
conjunctivitis 2.5% (placebo 4.9%)
dermatitis atopic 2.5% (placebo 13.1%)
NCT04033367 · Phase 4 · registry result, not featured evidence
injection site reaction 19.2%
arthralgia 11.5%
food allergy 7.7%
NCT04447417 · Phase 4 · registry result, not featured evidence
300 mg EOW
conjunctivitis 10.6%
dermatitis atopic 9.7%
nasopharyngitis 8.2%
NCT03738397 · Phase 3 · registry result, not featured evidence
300 mg Q2W
dermatitis atopic 43.9% (placebo 49.4%)
upper respiratory tract infection 17.1% (placebo 12%)
protein urine present 11% (placebo 10.8%)
NCT03912259 · Phase 3 · registry result, not featured evidence
300 mg Q2W
nasopharyngitis 20.6% (placebo 16.7%)
conjunctivitis allergic 15% (placebo 6.5%)
conjunctivitis 11.2% (placebo 3.7%)
NCT02755649 · Phase 3 · registry result, not featured evidence · combination
300 mg QW
nasopharyngitis 16.4% (placebo 16.7%)
headache 10% (placebo 9.3%)
conjunctivitis allergic 9.1% (placebo 6.5%)
NCT02755649 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 15% (placebo 10%)
other orthopedic injuries/procedures 12.5% (placebo 5%)
conjuctivitis 10% (placebo 0%)
NCT03359356 · Phase 2 · registry result, not featured evidence
4 mg/kg
nasopharyngitis 40%
dermatitis atopic 15%
abdominal pain upper 10%
NCT02407756 · Phase 2 · registry result, not featured evidence
4 mg/kg
nasopharyngitis 52.6%
cough 36.8%
dermatitis atopic 26.3%
NCT02407756 · Phase 2 · registry result, not featured evidence
2mg/kg
dermatitis atopic 10%
influenza 10%
nasopharyngitis 10%
NCT02407756 · Phase 2 · registry result, not featured evidence
2mg/kg
dermatitis atopic 27.8%
nasopharyngitis 27.8%
cheilitis 5.6%
NCT02407756 · Phase 2 · registry result, not featured evidence
300 mg qw
upper respiratory tract infection 11.3% (placebo 14.4%)
conjunctivitis 8.2% (placebo 0%)
headache 5.2% (placebo 3.1%)
NCT02210780 · Phase 2 · registry result, not featured evidence
200 mg qw
dermatitis atopic 14.8% (placebo 14.8%)
upper respiratory tract infection 14.8% (placebo 14.8%)
nasopharyngitis 11.1% (placebo 18.5%)
NCT01979016 · Phase 2 · registry result, not featured evidence
300 mg q2w
nasopharyngitis 25% (placebo 26.2%)
dermatitis atopic 20.3% (placebo 16.4%)
upper respiratory tract infection 9.4% (placebo 18%)
NCT01859988 · Phase 2 · registry result, not featured evidence
300 mg q4w
nasopharyngitis 32.3% (placebo 26.2%)
dermatitis atopic 15.4% (placebo 16.4%)
headache 7.7% (placebo 3.3%)
NCT01859988 · Phase 2 · registry result, not featured evidence
300 mg qw
nasopharyngitis 25.4% (placebo 26.2%)
dermatitis atopic 12.7% (placebo 16.4%)
headache 12.7% (placebo 3.3%)
NCT01859988 · Phase 2 · registry result, not featured evidence
200 mg q2w
nasopharyngitis 26.2% (placebo 26.2%)
headache 14.8% (placebo 3.3%)
dermatitis atopic 13.1% (placebo 16.4%)
NCT01859988 · Phase 2 · registry result, not featured evidence
100 mg q4w
nasopharyngitis 30.8% (placebo 26.2%)
dermatitis atopic 16.9% (placebo 16.4%)
headache 10.8% (placebo 3.3%)
NCT01859988 · Phase 2 · registry result, not featured evidence
300 mg
nasopharyngitis 40% (placebo 18.5%)
headache 16.4% (placebo 13%)
conjunctivitis 14.5% (placebo 3.7%)
NCT01548404 · Phase 2 · registry result, not featured evidence
300 mg
nasopharyngitis 23.8% (placebo 20%)
headache 14.3% (placebo 10%)
oropharyngeal pain 14.3% (placebo 10%)
NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

dupilumab

IGA 0/1 0% (n=10) @ 4wk6 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT03346434 · Phase 2/3
show 26 more results
10% (n=10) @ 4wk6 mg/kg
NCT03346434 · Phase 2/3
10% (n=10) @ 4wk3 mg/kg
NCT03346434 · Phase 2/3
10% (n=10) @ 4wk3 mg/kg
NCT03346434 · Phase 2/3
35% (n=20) @ 12wk4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
21.1% (n=19) @ 12wk4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
10% (n=20) @ 12wk2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
16.7% (n=18) @ 12wk2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
31.1% (n=2677) @ 4wk
NCT01949311 · Phase 3 · monotherapy
46.7% (n=2677) @ 16wk
NCT01949311 · Phase 3 · monotherapy
46.2% (n=2677) @ 36wk
NCT01949311 · Phase 3 · monotherapy
53.8% (n=2677) @ 52wk
NCT01949311 · Phase 3 · monotherapy
58.2% (n=2677) @ 100wk
NCT01949311 · Phase 3 · monotherapy
59.6% (n=2677) @ 124wk
NCT01949311 · Phase 3 · monotherapy
67.2% (n=2677) @ 156wk
NCT01949311 · Phase 3 · monotherapy
71.1% (n=2677) @ 172wk
NCT01949311 · Phase 3 · monotherapy
56.5% (n=2677) @ 188wk
NCT01949311 · Phase 3 · monotherapy
64.4% (n=2677) @ 204wk
NCT01949311 · Phase 3 · monotherapy
81.2% (n=2677) @ 220wk
NCT01949311 · Phase 3 · monotherapy
50% (n=2677) @ 236wk
NCT01949311 · Phase 3 · monotherapy
0.9% (n=120) @ 2wk
NCT05590585 · Phase 4 · registry result, not featured evidence
6.8% (n=120) @ 4wk
NCT05590585 · Phase 4 · registry result, not featured evidence
15.9% (n=120) @ 8wk
NCT05590585 · Phase 4 · registry result, not featured evidence
25.9% (n=120) @ 12wk
NCT05590585 · Phase 4 · registry result, not featured evidence
35.2% (n=120) @ 16wk
NCT05590585 · Phase 4 · registry result, not featured evidence
45.4% (n=120) @ 20wk
NCT05590585 · Phase 4 · registry result, not featured evidence
44% (n=120) @ 24wk
NCT05590585 · Phase 4 · registry result, not featured evidence
IGA 0/1 67.5% (n=2677) @ 272wk
responder rate · % of participants
No placebo or comparator arm
End of Study (Extension)
NCT01949311 · Phase 3 · monotherapy
EASI-75 65.3% (n=2677) @ 4wk
responder rate · % of participants
No placebo or comparator arm
NCT01949311 · Phase 3 · monotherapy
show 19 more results
82% (n=2677) @ 16wk
NCT01949311 · Phase 3 · monotherapy
85.3% (n=2677) @ 36wk
NCT01949311 · Phase 3 · monotherapy
88.8% (n=2677) @ 52wk
NCT01949311 · Phase 3 · monotherapy
91.4% (n=2677) @ 100wk
NCT01949311 · Phase 3 · monotherapy
92% (n=2677) @ 124wk
NCT01949311 · Phase 3 · monotherapy
89.5% (n=2677) @ 156wk
NCT01949311 · Phase 3 · monotherapy
94.1% (n=2677) @ 172wk
NCT01949311 · Phase 3 · monotherapy
96.8% (n=2677) @ 188wk
NCT01949311 · Phase 3 · monotherapy
90.9% (n=2677) @ 204wk
NCT01949311 · Phase 3 · monotherapy
93.5% (n=2677) @ 220wk
NCT01949311 · Phase 3 · monotherapy
100% (n=2677) @ 236wk
NCT01949311 · Phase 3 · monotherapy
3.4% (n=120) @ 2wk
NCT05590585 · Phase 4 · registry result, not featured evidence
23.1% (n=120) @ 4wk
NCT05590585 · Phase 4 · registry result, not featured evidence
50.4% (n=120) @ 8wk
NCT05590585 · Phase 4 · registry result, not featured evidence
56.5% (n=120) @ 12wk
NCT05590585 · Phase 4 · registry result, not featured evidence
63.9% (n=120) @ 16wk
NCT05590585 · Phase 4 · registry result, not featured evidence
74.2% (n=120) @ 20wk
NCT05590585 · Phase 4 · registry result, not featured evidence
76% (n=120) @ 24wk
NCT05590585 · Phase 4 · registry result, not featured evidence
76% (n=100) @ 24wk
NCT05590585 · Phase 4 · registry result, not featured evidence
EASI-75 88.9% (n=2677) @ 272wk
responder rate · % of participants
No placebo or comparator arm
End of Study (Extension)
NCT01949311 · Phase 3 · monotherapy
IGA Leq2 70% (n=2677) @ 4wk
responder rate · % of participants
No placebo or comparator arm
NCT01949311 · Phase 3 · monotherapy
show 11 more results
83% (n=2677) @ 16wk
NCT01949311 · Phase 3 · monotherapy
84.6% (n=2677) @ 36wk
NCT01949311 · Phase 3 · monotherapy
89.6% (n=2677) @ 52wk
NCT01949311 · Phase 3 · monotherapy
90.9% (n=2677) @ 100wk
NCT01949311 · Phase 3 · monotherapy
93.1% (n=2677) @ 124wk
NCT01949311 · Phase 3 · monotherapy
94.8% (n=2677) @ 156wk
NCT01949311 · Phase 3 · monotherapy
96.3% (n=2677) @ 172wk
NCT01949311 · Phase 3 · monotherapy
96.8% (n=2677) @ 188wk
NCT01949311 · Phase 3 · monotherapy
96% (n=2677) @ 204wk
NCT01949311 · Phase 3 · monotherapy
97.1% (n=2677) @ 220wk
NCT01949311 · Phase 3 · monotherapy
90% (n=2677) @ 236wk
NCT01949311 · Phase 3 · monotherapy
IGA Leq2 92.6% (n=2677) @ 272wk
responder rate · % of participants
No placebo or comparator arm
End of Study (Extension)
NCT01949311 · Phase 3 · monotherapy
EASI -8.59 score @ 4wk
absolute change · score
No placebo or comparator arm
NCT01949311 · Phase 3 · monotherapy
show 22 more results
-11.89 score @ 16wk
NCT01949311 · Phase 3 · monotherapy
-17.32 score @ 36wk
NCT01949311 · Phase 3 · monotherapy
-16.46 score @ 52wk
NCT01949311 · Phase 3 · monotherapy
-17.99 score @ 100wk
NCT01949311 · Phase 3 · monotherapy
-17.68 score @ 124wk
NCT01949311 · Phase 3 · monotherapy
-14.23 score @ 156wk
NCT01949311 · Phase 3 · monotherapy
-13.23 score @ 172wk
NCT01949311 · Phase 3 · monotherapy
-19.24 score @ 188wk
NCT01949311 · Phase 3 · monotherapy
-14.5 score @ 204wk
NCT01949311 · Phase 3 · monotherapy
-12.75 score @ 220wk
NCT01949311 · Phase 3 · monotherapy
-16.69 score @ 236wk
NCT01949311 · Phase 3 · monotherapy
-7.105 score @ 2wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-12.097 score @ 4wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-17.779 score @ 8wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-18.475 score @ 12wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-19.46 score @ 16wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-20.985 score @ 20wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-20.98 score @ 24wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-18.9 score @ 17wk
NCT04823130 · Phase 4 · registry result, not featured evidence
-19.5 score @ 21wk
NCT04823130 · Phase 4 · registry result, not featured evidence
10.6 score @ 24wk
NCT03359356 · Phase 2 · registry result, not featured evidence
10.53 score @ 48wk
NCT03359356 · Phase 2 · registry result, not featured evidence
EASI -13.14 score @ 272wk
absolute change · score
No placebo or comparator arm
End of Study (Extension)
NCT01949311 · Phase 3 · monotherapy
EASI -48.7% (n=10) @ 4wk6 mg/kg
percent change · % of baseline
No placebo or comparator arm
NCT03346434 · Phase 2/3
show 26 more results
-43.2% (n=10) @ 4wk6 mg/kg
NCT03346434 · Phase 2/3
-26.6% (n=10) @ 4wk3 mg/kg
NCT03346434 · Phase 2/3
-22.4% (n=10) @ 4wk3 mg/kg
NCT03346434 · Phase 2/3
-69.7% (n=20) @ 12wk4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
-63.4% (n=19) @ 12wk4mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
-66.4% (n=20) @ 12wk2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
-76.2% (n=18) @ 12wk2mg/kg
NCT02407756 · Phase 2 · registry result, not featured evidence
-42.02% (n=2677) @ 4wk
NCT01949311 · Phase 3 · monotherapy
-54.82% (n=2677) @ 16wk
NCT01949311 · Phase 3 · monotherapy
-60.4% (n=2677) @ 36wk
NCT01949311 · Phase 3 · monotherapy
-75.76% (n=2677) @ 52wk
NCT01949311 · Phase 3 · monotherapy
-82.61% (n=2677) @ 100wk
NCT01949311 · Phase 3 · monotherapy
-84.15% (n=2677) @ 124wk
NCT01949311 · Phase 3 · monotherapy
-83.45% (n=2677) @ 156wk
NCT01949311 · Phase 3 · monotherapy
-74.98% (n=2677) @ 172wk
NCT01949311 · Phase 3 · monotherapy
-88.72% (n=2677) @ 188wk
NCT01949311 · Phase 3 · monotherapy
-70.91% (n=2677) @ 204wk
NCT01949311 · Phase 3 · monotherapy
-30.79% (n=2677) @ 220wk
NCT01949311 · Phase 3 · monotherapy
-87.56% (n=2677) @ 236wk
NCT01949311 · Phase 3 · monotherapy
-25.929% (n=120) @ 2wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-46.092% (n=120) @ 4wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-67.27% (n=120) @ 8wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-70.999% (n=120) @ 12wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-73.276% (n=120) @ 16wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-79.185% (n=120) @ 20wk
NCT05590585 · Phase 4 · registry result, not featured evidence
-79.941% (n=120) @ 24wk
NCT05590585 · Phase 4 · registry result, not featured evidence
EASI -55.44% (n=2677) @ 272wk
percent change · % of baseline
No placebo or comparator arm
End of Study (Extension)
NCT01949311 · Phase 3 · monotherapy
EASI-50 86% (n=2677) @ 4wk
responder rate · % of participants
No placebo or comparator arm
NCT01949311 · Phase 3 · monotherapy
show 18 more results
95% (n=2677) @ 16wk
NCT01949311 · Phase 3 · monotherapy
96.7% (n=2677) @ 36wk
NCT01949311 · Phase 3 · monotherapy
97.4% (n=2677) @ 52wk
NCT01949311 · Phase 3 · monotherapy
98.5% (n=2677) @ 100wk
NCT01949311 · Phase 3 · monotherapy
98.3% (n=2677) @ 124wk
NCT01949311 · Phase 3 · monotherapy
97.4% (n=2677) @ 156wk
NCT01949311 · Phase 3 · monotherapy
98.4% (n=2677) @ 172wk
NCT01949311 · Phase 3 · monotherapy
100% (n=2677) @ 188wk
NCT01949311 · Phase 3 · monotherapy
94.9% (n=2677) @ 204wk
NCT01949311 · Phase 3 · monotherapy
97.8% (n=2677) @ 220wk
NCT01949311 · Phase 3 · monotherapy
100% (n=2677) @ 236wk
NCT01949311 · Phase 3 · monotherapy
17.2% (n=120) @ 2wk
NCT05590585 · Phase 4 · registry result, not featured evidence
47.9% (n=120) @ 4wk
NCT05590585 · Phase 4 · registry result, not featured evidence
77.9% (n=120) @ 8wk
NCT05590585 · Phase 4 · registry result, not featured evidence
84.3% (n=120) @ 12wk
NCT05590585 · Phase 4 · registry result, not featured evidence
84.3% (n=120) @ 16wk
NCT05590585 · Phase 4 · registry result, not featured evidence
89.7% (n=120) @ 20wk
NCT05590585 · Phase 4 · registry result, not featured evidence
89% (n=120) @ 24wk
NCT05590585 · Phase 4 · registry result, not featured evidence
EASI-50 96.9% (n=2677) @ 272wk
responder rate · % of participants
No placebo or comparator arm
End of Study (Extension)
NCT01949311 · Phase 3 · monotherapy

+ 127 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dupilumab's landscape · SHR-1819's landscape